EEG Biomarkers for Predicting Response to Antidepressant Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00289523|
Recruitment Status : Completed
First Posted : February 10, 2006
Last Update Posted : March 7, 2012
The purpose of this study is to evaluate the potential early EEG predictors of an individual's response to treatment with antidepressant medications.
- Prospectively confirm accuracy of current EEG biomarker algorithm
- Determine preferred clinical intervention for subjects with negative indicator
- Identify predictors of worsening suicide ideation
|Condition or disease||Phase|
|Major Depressive Disorder||Phase 4|
According to recent clinical studies sponsored by the NIH, fewer than half of subjects diagnosed with a major depressive episode respond to the first trial of an antidepressant medication. While the majority of subjects eventually respond to treatment with an antidepressant, failure with the first line medication puts subjects at increased risk for never receiving adequate treatment of their depression.
Several lines of reasoning support the rationale for further investigating EEG as a means of predicting response and resistance to antidepressants. Prior studies suggest that changes in neuronal activity in the anterior cingulate and prefrontal regions are related to depression and that changes in brain response to treatment may also produce alterations that can be detected by recoding frontal EEG activity.
In this protocol, we proposed to identify possible neurophysiologic indicators of treatment outcome in depression, particularly indicators of brain response that appear early (within 7 days) during treatment with antidepressants. We will test whether quantitative EEG (QEEG) biomarkers can be reliably associated with response or non-response to treatment with antidepressant medications, using both monotherapy and combination drug treatments.
Selecting the best treatment for subjects with resistance to an initial antidepressant poses a considerable challenge for clinicians. The most widely prescribed antidepressants usually require 4-6 weeks of therapeutic dosing before a marked clinical improvement in symptoms is observed. Therefore, determining the optimal regimen can take several weeks or months for subjects who are resistant to the first line antidepressant. A tool for predicting eventual clinical response to antidepressants could help inform and accelerate the process of identifying the most efficacious treatment option for a given subject.
|Study Type :||Observational|
|Actual Enrollment :||375 participants|
|Observational Model:||Case Control|
|Official Title:||Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD), a Prospective, Randomized, Multi-center Study to Determine the Efficacy of Selected EEG and Genotype Biomarkers for Predicting Response to Antidepressant Therapy With Escitalopram, Bupropion XL, or a Combination Treatment Regimen.|
|Study Start Date :||January 2006|
|Primary Completion Date :||July 2007|
|Study Completion Date :||July 2007|
Escitalopram and Bupropion XL
- 1. To confirm prospectively the accuracy of an EEG biomarker as a leading indicator of SSRI antidepressant treatment response; [ Time Frame: 8 weeks ]2. To identify the optimal positive and negative indicators of response to initial treatment with an SSRI; 3. To determine the preferred clinical intervention to perform following an initial negative treatment response indicator;
- 1. To confirm prospectively the accuracy of an EEG biomarker as a leading indicator of remission; [ Time Frame: 8 weeks ]2. To explore the relationship between EEG and genetic biomarkers as predictors of treatment response and remission; 3. To determine if certain baseline EEG values or changes early in the course of treatment may predict the emergence of worsening suicidal ideation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00289523
|United States, California|
|University of California, Los Angeles-Westwood|
|Los Angeles, California, United States, 90024|
|Cedars-Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|University of California, San Diego|
|San Diego, California, United States, 92161|
|University of California, Los Angeles-Harbor|
|Torrance, California, United States, 90509|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Pennsylvania|
|University of Pittsburgh|
|Pittsburgh, Pennsylvania, United States, 15213|
|United States, Texas|
|University of Texas, Southwestern|
|Dallas, Texas, United States, 75235|
|Baylor University College of Medicine|
|Houston, Texas, United States, 77030|
|R/D Clinical Research, Inc.|
|Lake Jackson, Texas, United States, 77566|
|Principal Investigator:||Andrew F Leuchter, M.D.||University of California, Los Angeles-Westwood|